AXSOME THERAPEUTICS, INC. (AXSM) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $70.00M; Long-term Debt, Excluding Current MaturitiesUSD $117.96M; Long-Term Debt, Maturity, Year FourUSD $120.00M; Long-Term Debt, Maturity, Year FiveUSD (m).
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $70.00M; Long-term Debt, Excluding Current MaturitiesUSD $117.85M; Long-Term Debt, Maturity, Year FourUSD $120.00M; Long-Term Debt, Maturity, Year FiveUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $70.00M; Long-term Debt, Excluding Current MaturitiesUSD $117.75M; Long-Term Debt, Maturity, Year FourUSD (m); Long-Term Debt, Maturity, Year FiveUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-Term Debt, Maturity, Year FourUSD (m); Long-Term Debt, Maturity, Year FiveUSD $120.00M.
AXSOME THERAPEUTICS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Line of Credit Facility, Maximum Borrowing Capacity USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount, Noncurrent USD | Convertible Notes Payable USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Debt Instrument, Unamortized Discount, Current USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $70.00M | $117.96M | $120.00M | (m) | (m) | (m) | $120.00M | $2.04M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $70.00M | $117.85M | $120.00M | (m) | (m) | (m) | $120.00M | $2.15M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $70.00M | $117.75M | (m) | (m) | (m) | (m) | $120.00M | $2.25M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | $120.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $70.00M | $117.64M | (m) | (m) | $120.00M | (m) | $120.00M | $2.36M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $70.00M | $117.54M | (m) | (m) | $120.00M | (m) | $120.00M | $2.46M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $181.38M | $180.00M | (m) | (m) | (m) | $180.00M | $3.10M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $180.71M | (m) | (m) | (m) | (m) | $180.00M | $3.38M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $180.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $180.00M | (m) | $180.00M | (m) | (m) | $180.00M | $3.69M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $179.33M | (m) | $180.00M | (m) | (m) | $180.00M | $3.99M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $178.69M | (m) | $180.00M | (m) | (m) | $180.00M | $4.27M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $178.07M | (m) | (m) | (m) | (m) | $180.00M | $4.54M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | $180.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $177.45M | (m) | (m) | $180.00M | (m) | $180.00M | $4.82M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $176.82M | (m) | (m) | $180.00M | (m) | $180.00M | $5.11M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $147.62M | (m) | (m) | $150.00M | (m) | $150.00M | $4.05M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-01-09 | (m) | (m) | (m) | (m) | (m) | $350.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $94.26M | (m) | (m) | (m) | (m) | $95.00M | $2.10M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $15.20M | $79.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $93.91M | $79.80M | (m) | (m) | (m) | $95.00M | $2.24M | (m) | (m) | (m) | $15.20M | (m) | (m) |
| 2022-06-30 | (m) | $93.46M | $79.80M | (m) | (m) | (m) | $95.00M | $2.49M | (m) | (m) | (m) | $15.20M | (m) | (m) |
| 2022-03-31 | (m) | $49.31M | $41.97M | (m) | (m) | (m) | $50.00M | $1.49M | (m) | (m) | (m) | $8.03M | (m) | (m) |
| 2021-12-31 | (m) | $49.09M | (m) | (m) | (m) | (m) | $50.00M | $1.62M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $8.03M | $41.97M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $49.17M | $18.05M | (m) | (m) | (m) | $50.00M | $1.43M | (m) | (m) | $12.19M | $19.76M | (m) | (m) |
| 2021-06-30 | (m) | $48.88M | $18.05M | (m) | (m) | (m) | $50.00M | $1.56M | (m) | (m) | $12.19M | $19.76M | (m) | (m) |
| 2021-03-31 | (m) | $48.60M | $18.05M | (m) | (m) | (m) | $50.00M | $1.70M | (m) | (m) | $12.19M | $19.76M | (m) | (m) |
| 2020-12-31 | (m) | $48.32M | (m) | (m) | (m) | (m) | $50.00M | $1.83M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $19.76M | $18.05M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $12.19M | (m) | (m) |
| 2020-09-30 | (m) | $48.03M | $19.81M | $17.95M | (m) | (m) | $50.00M | $1.98M | (m) | (m) | (m) | $12.24M | (m) | (m) |
| 2020-06-30 | $6.55M | $13.74M | $1.33M | (m) | (m) | (m) | $20.00M | $231.40K | (m) | (m) | $8.00M | $8.00M | $2.67M | $119.41K |
| 2020-03-31 | $4.57M | $15.54M | $1.33M | (m) | (m) | (m) | $20.00M | $312.57K | (m) | (m) | $8.00M | $8.00M | $2.67M | $98.23K |
| 2019-12-31 | $2.60M | $17.33M | (m) | (m) | (m) | (m) | $20.00M | $405.07K | (m) | (m) | (m) | (m) | (m) | $64.38K |
| 2019-12-31 | (m) | (m) | $1.33M | (m) | (m) | (m) | (m) | (m) | (m) | $2.67M | $8.00M | $8.00M | (m) | (m) |
| 2019-09-30 | $648.52K | $19.11M | $8.00M | $1.33M | (m) | (m) | $20.00M | $509.23K | (m) | (m) | $2.67M | $8.00M | (m) | $18.14K |
| 2019-06-30 | $2.16M | $17.42M | $6.67M | $555.56K | (m) | (m) | $20.00M | $516.78K | (m) | (m) | $6.11M | $6.67M | (m) | $67.20K |
| 2019-03-31 | $535.77K | $18.82M | $6.67M | $555.56K | (m) | (m) | $20.00M | $664.31K | (m) | (m) | $6.11M | $6.67M | (m) | $19.79K |
| 2018-12-31 | $3.29M | $3.62M | (m) | (m) | (m) | (m) | $6.39M | $99.59K | (m) | (m) | (m) | (m) | (m) | $41.94K |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.33M | $3.06M | (m) | (m) |
| 2018-09-30 | $3.29M | $4.44M | (m) | (m) | (m) | (m) | $7.22M | $551.49K | (m) | (m) | $3.33M | $3.06M | $833.33K | $47.78K |
| 2018-06-30 | $3.28M | $5.19M | (m) | (m) | (m) | (m) | $8.06M | $468.29K | (m) | (m) | $3.33M | $3.06M | $1.67M | $53.16K |
| 2018-03-31 | $3.28M | $5.93M | (m) | (m) | (m) | (m) | $8.89M | $376.63K | (m) | (m) | $3.33M | $3.06M | $2.50M | $58.02K |
| 2017-12-31 | $3.27M | $6.66M | (m) | (m) | (m) | (m) | $9.72M | $274.12K | (m) | (m) | (m) | (m) | (m) | $63.99K |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | $3.33M | $3.33M | $3.06M | (m) | (m) |
| 2017-09-30 | $2.72M | $7.38M | $3.06M | (m) | (m) | (m) | $10.00M | $153.22K | (m) | (m) | $3.33M | $3.33M | $277.78K | $60.74K |
| 2017-06-30 | $1.90M | $8.08M | $3.06M | (m) | (m) | (m) | $10.00M | $21.51K | (m) | (m) | $3.33M | $3.33M | $277.78K | $48.65K |
| 2017-03-31 | $1.08M | $8.78M | $3.06M | (m) | (m) | (m) | $10.00M | (m) | (m) | $277.78K | $3.33M | $3.33M | (m) | (m) |
| 2016-12-31 | $269.16K | $9.47M | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $3.06M | (m) | (m) | (m) | $10.00M | (m) | (m) | $277.78K | $3.33M | $3.33M | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |